Gabriela Gruia

Dr. Gruia most recently served as Chief Development Officer at Ichnos Sciences where she oversaw regulatory sciences, clinical operations, drug safety, clinical pharmacology, biostatistics, and clinical outsourcing. Prior to joining Ichnos, Dr. Gruia spent 16 years at Novartis where she served in several senior roles of increasing responsibility, including Senior Vice President and Global Head of Drug Regulatory Affairs Oncology and Head of Medical Writing and Submissions. At Novartis, Dr. Gruia lead the world-class oncology regulatory affairs organization of approximately 120 associates and managed all regulatory activities in close partnership with research collaborators, preclinical development, development organization, and senior management. Previously, Dr. Gruia held oncology research and development roles at Pfizer, Pharmacia, Aventis, and Rhone Poulenc Rorer. Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Center in Paris, France. She received her training in oncology and hematology from Rene Descartes University in Paris, France.